To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
Shire’s strategic goal is to become the leading specialty biopharmaceutical company, focusing on meeting the needs of specialist physicians. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. To this end, Shire primarily orients its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are indicated for said disorder. However, the company also puts interest in gastrointestinal (GI) treatments, renal diseases, and human genetic therapies (HGT). This structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.
Shire’s focused strategy is to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
Shire announced the acquisition of New River Pharmaceuticals on 20th February 2007.
Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The non-executive Board Chairman is Dr. James Cavanaugh. The President of the Human Genetic Therapies division is Sylvie Gregoire and Mike Cola is the President of Specialty Pharmaceuticals.
Key marketed products by business unit (with indications)
Human Genetic Therapies
Shire is traded on three stock exchanges:
Shire's financial reports can be found at http://www.shire.com/shire/InvestorRelations/reports.jsp?tn=2&m1=22.
The corporate offices are located in Basingstoke, Hampshire. The address is:
Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. Plus, Shire owns a manufacturing site in Owings Mills, Maryland.
3i · Admiral Group · Alliance & Leicester · AMEC · Anglo American · Antofagasta · Associated British Foods · AstraZeneca · Aviva · BAE Systems · BG Group · BHP Billiton · BP · BT Group · Barclays Bank · British Airways · British American Tobacco · British Energy Group · British Land Company · British Sky Broadcasting Group · Cable & Wireless · Cadbury Schweppes · Cairn Energy · Capita Group · Carnival · Carphone Warehouse · Centrica · Compass Group · Diageo · Enterprise Inns · Experian · FirstGroup · Friends Provident · G4S · GlaxoSmithKline · HBOS · HSBC · Hammerson · Home Retail Group · ICAP · ITV · Imperial Tobacco · InterContinental Hotels Group · International Power · Johnson Matthey · Kazakhmys · Kelda Group · Kingfisher · Land Securities Group · Legal & General · Liberty International · Lloyds TSB · London Stock Exchange Group · Lonmin · Man Group · Marks & Spencer · Wm Morrison Supermarkets · National Grid · Next · Old Mutual · Pearson · Persimmon · Prudential · Reckitt Benckiser · Reed Elsevier · Rentokil Initial · Resolution · Reuters Group · Rexam · Rio Tinto Group · Rolls-Royce Group · Royal & Sun Alliance Insurance · Royal Bank of Scotland Group · Royal Dutch Shell · SABMiller · Sage Group · J Sainsbury · Schroders · Scottish & Newcastle · Scottish and Southern Energy · Severn Trent · Shire Pharmaceuticals Group · Smith & Nephew · Smiths Group · Standard Chartered Bank · Standard Life · Taylor Wimpey · Tesco · Thomas Cook Group · TUI Travel · Tullow Oil · Unilever · United Utilities · Vedanta Resources · Vodafone · WPP Group · Whitbread · Wolseley · Xstrata · Yell Group